Hepatorenal syndrome in patients with cirrhosis.
Type 1 hepatorenal syndrome (HRS) is a severe complication of end-stage cirrhosis. Type 1 HRS is an acute functional renal failure (i.e. glomerular hypofiltration) with no other explanation than the presence of the circulatory and neurohumoral alterations associated with severe chronic liver disease. Plasma volume expansion does not improve renal function. In contrast, administration of the vasopressin analog terlipressin, a splanchnic and systemic vasoconstrictor, may improve renal function and be used while awaiting liver transplantation.
Moreau
Richard
R
Laboratoire d' Hémodynamique Splanchnique et de Biologie Vasculaire, INSERM U-481, and Service d' Hépatologie, Hôpital Beaujon, Clichy, France. rmoreau@bichat.inserm.fr
D006530:Hepatorenal Syndrome / Q000175:diagnosis / Q000209:etiology* / Q000628:therapy; D006801:Humans; D008103:Liver Cirrhosis / Q000150:complications*; D016031:Liver Transplantation; D008236:Lypressin / Q000031:analogs & derivatives / Q000627:therapeutic use; D011322:Primary Prevention; D011379:Prognosis; D000077585:Terlipressin; D016896:Treatment Outcome; D014662:Vasoconstrictor Agents / Q000627:therapeutic use
D014662:Vasoconstrictor Agents; D008236:Lypressin; D000077585:Terlipressin